These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

558 related items for PubMed ID: 24172860

  • 1. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis.
    Lei X, Reheman A, Hou Y, Zhou H, Wang Y, Marshall AH, Liang C, Dai X, Li BX, Vanhoorelbeke K, Ni H.
    Thromb Haemost; 2014 Feb; 111(2):279-89. PubMed ID: 24172860
    [Abstract] [Full Text] [Related]

  • 2. In vitro assessment and phase I randomized clinical trial of anfibatide a snake venom derived anti-thrombotic agent targeting human platelet GPIbα.
    Li BX, Dai X, Xu XR, Adili R, Neves MAD, Lei X, Shen C, Zhu G, Wang Y, Zhou H, Hou Y, Ni T, Pasman Y, Yang Z, Qian F, Zhao Y, Gao Y, Liu J, Teng M, Marshall AH, Cerenzia EG, Li ML, Ni H.
    Sci Rep; 2021 Jun 03; 11(1):11663. PubMed ID: 34083615
    [Abstract] [Full Text] [Related]

  • 3. A novel snake venom-derived GPIb antagonist, anfibatide, protects mice from acute experimental ischaemic stroke and reperfusion injury.
    Li TT, Fan ML, Hou SX, Li XY, Barry DM, Jin H, Luo SY, Kong F, Lau LF, Dai XR, Zhang GH, Zhou LL.
    Br J Pharmacol; 2015 Aug 03; 172(15):3904-16. PubMed ID: 25917571
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mutant botrocetin-2 inhibits von Willebrand factor-induced platelet agglutination.
    Matsui T, Hori A, Hamako J, Matsushita F, Ozeki Y, Sakurai Y, Hayakawa M, Matsumoto M, Fujimura Y.
    J Thromb Haemost; 2017 Mar 03; 15(3):538-548. PubMed ID: 28071872
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Trowaglerix Venom Polypeptides As a Novel Antithrombotic Agent by Targeting Immunoglobulin-Like Domains of Glycoprotein VI in Platelet.
    Chang CH, Chung CH, Tu YS, Tsai CC, Hsu CC, Peng HC, Tseng YJ, Huang TF.
    Arterioscler Thromb Vasc Biol; 2017 Jul 03; 37(7):1307-1314. PubMed ID: 28596377
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Characterization of murine anti-glycoprotein Ib monoclonal antibodies that differentiate between shear-induced and ristocetin/botrocetin-induced glycoprotein Ib-von Willebrand factor interaction.
    Cauwenberghs N, Ajzenberg N, Vauterin S, Hoylaerts MF, Declerck PJ, Baruch D, Deckmyn H.
    Haemostasis; 2000 Jul 03; 30(3):139-48. PubMed ID: 11014964
    [Abstract] [Full Text] [Related]

  • 10. Adhesion of blood platelets is inhibited by VCL, a recombinant fragment (leucine504 to lysine728) of von Willebrand factor.
    Sixma JJ, Ijsseldijk MJ, Hindriks G, van Zanten GH, Gorecki M, Panet A, Garfinkel LI, de Groot PG.
    Arterioscler Thromb Vasc Biol; 1996 Jan 03; 16(1):64-71. PubMed ID: 8548428
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. How does agkicetin-C bind on platelet glycoprotein Ibalpha and achieve its platelet effects?
    Xu G, Ulrichts H, Vauterin S, De Meyer SF, Deckmyn H, Teng M, Niu L.
    Toxicon; 2005 Apr 03; 45(5):561-70. PubMed ID: 15777951
    [Abstract] [Full Text] [Related]

  • 14. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
    Yuan Y, Zhang W, Yan R, Liao Y, Zhao L, Ruan C, Du X, Dai K.
    Circ Res; 2009 Dec 04; 105(12):1177-85. PubMed ID: 19875727
    [Abstract] [Full Text] [Related]

  • 15. Antithrombotic effect of a protein-type I class snake venom metalloproteinase, kistomin, is mediated by affecting glycoprotein Ib-von Willebrand factor interaction.
    Hsu CC, Wu WB, Chang YH, Kuo HL, Huang TF.
    Mol Pharmacol; 2007 Oct 04; 72(4):984-92. PubMed ID: 17609416
    [Abstract] [Full Text] [Related]

  • 16. Conformational changes in the A3 domain of von Willebrand factor modulate the interaction of the A1 domain with platelet glycoprotein Ib.
    Obert B, Houllier A, Meyer D, Girma JP.
    Blood; 1999 Mar 15; 93(6):1959-68. PubMed ID: 10068669
    [Abstract] [Full Text] [Related]

  • 17. Dual roles of fucoidan-GPIbα interaction in thrombosis and hemostasis: implications for drug development targeting GPIbα.
    Shen C, Mackeigan DT, Shoara AA, Xu R, Bhoria P, Karakas D, Ma W, Cerenzia E, Chen Z, Hoard B, Lin L, Lei X, Zhu G, Chen P, Johnson PE, Ni H.
    J Thromb Haemost; 2023 May 15; 21(5):1274-1288. PubMed ID: 36732162
    [Abstract] [Full Text] [Related]

  • 18. The antithrombotic effect of aurin tricarboxylic acid in the guinea pig is not solely due to its interaction with the von Willebrand factor-GPIb axis.
    Azzam K, Cissé-Thiam M, Drouet L.
    Thromb Haemost; 1996 Jan 15; 75(1):203-10. PubMed ID: 8713802
    [Abstract] [Full Text] [Related]

  • 19. N1421K mutation in the glycoprotein Ib binding domain impairs ristocetin- and botrocetin-mediated binding of von Willebrand factor to platelets.
    Lanke E, Kristoffersson AC, Isaksson C, Holmberg L, Lethagen S.
    Eur J Haematol; 2008 Nov 15; 81(5):384-90. PubMed ID: 18637125
    [Abstract] [Full Text] [Related]

  • 20. Isolation and characterization of jararaca GPIb-BP, a snake venom antagonist specific to platelet glycoprotein Ib.
    Fujimura Y, Ikeda Y, Miura S, Yoshida E, Shima H, Nishida S, Suzuki M, Titani K, Taniuchi Y, Kawasaki T.
    Thromb Haemost; 1995 Aug 15; 74(2):743-50. PubMed ID: 8585016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.